policy
Guidelines for use of autogenous biologics
Autogenous biological products may provide veterinarians a unique opportunity for control of certain infectious diseases when USDA-licensed commercial…
policy
Development of emerging disease agent biologics
Development of emerging infectious disease biologics is essential for One Health. The AVMA supports the development of these products through…
policy
Dietary Supplement Health and Education Act of 1994
The Dietary Supplement Health and Education Act of 1994, which defines dietary supplements for use in humans, does not apply to products intended for…
policy
Funding of the New Animal Drug Application (NADA) and Abbreviated New Animal Drug Application (ANADA) approval process
To help ensure adequate availability of veterinary drugs, the AVMA supports increased funding of the FDA Center for Veterinary Medicine for the NADA…
policy
Adverse event reporting
The AVMA encourages veterinarians to report adverse events, and encourages continued development and strengthening of adverse event reporting systems.
Antimicrobial use and resistance: FAQs for pet owners
AVMA's antimicrobial FAQs provide science-based information to help you make educated decisions about the use of antibiotics and other antimicrobial…
JAVMA news
Cephalosporin use restricted in livestock
The Food and Drug Administration is increasing restrictions on extralabel use of cephalosporin-class antimicrobials in most food animals starting…
JAVMA news
Looking ahead
Dr. Clark K. Fobian, District VII representative to the AVMA Executive Board, will likely be elected AVMA president-elect by the AVMA House of…
Disease risks for dogs in social settings
The following is a list of the most common diseases to which your dog(s) may be exposed at a dog gathering. There may be specific risks in your area…
Controlled substances in veterinary practice
The veterinary toolbox includes vital medications that are regulated as controlled substances. Here's what veterinarians and veterinary teams need to…